J Nanobiotechnology July 2023 PMID 37403095

Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy.

Songlin Liu, Haiyang Wang, Xinzhe Shao, Haonan Chen, Shushu Chao, Yanyan Zhang, Zhaoju Gao, Qingqiang Yao, Pingping Zhang

Download social card

Mentions

Peak: 2 in Jul 2023

across 2 sources since Jul 2023

Extended reach

336

potential audience

Total likes

Video views

Mentions per month

Jul 2023 – Oct 2023

Where it's discussed

X / Twitter2 posts
YouTube1 videos

AI synopsis

What people are saying

The discussions highlight the significance of nanomaterials for targeted therapies, with phrases like 'promising results' and 'potential to transform treatment' indicating enthusiasm and recognition of impact. The tone combines technical interest with optimistic projections about the role of nanodelivery systems in advancing tumor therapy.

AgreementModerate agreement

Most comments agree that the research offers promising advancements in cancer treatment via nanodelivery systems for PD-1 inhibition.

InterestHigh interest

Discussions demonstrate high interest, with mentions of potential clinical applications and interest in the technical details of nanocarrier systems.

EngagementModerate engagement

Comments reference specific methods like targeted drug delivery and combination therapies, indicating a moderate level of detailed engagement.

ImpactModerate impact

Evaluations suggest that the article could influence future cancer immunotherapy research and treatment strategies, though the overall influence is viewed as promising but not yet revolutionary.

Abstract in brief

Recent advances in cancer immunotherapy include using nanodelivery systems to improve PD1 blockade therapy, which has shown promising results in treating various tumors like melanoma and lung cancer.
Nanomaterials offer unique advantages such as targeted drug delivery, combination therapy, and controlled release, helping to overcome current limitations like low responsiveness and immune-related side effects.
The review discusses how nanocarriers are used for delivering PD1 inhibitors alone or together with other treatments like immunomodulators and chemotherapeutic agents, providing valuable insights for developing improved cancer therapies.

Read the full abstract

All mentions

Enhancing Tumor Therapy with PD-1 Inhibition and Nano-Delivery Systems

Recent advances in cancer immunotherapy include using nanodelivery systems to improve PD1 blockade therapy, which has shown promising results in treating various tumors like melanoma and lung cancer.

STEM RTCL TV · Oct 18, 2023 2 views

LungOmics

@LungOmics · X

Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy https://t.co/5haylSkZN8 https://t.co/nAOJ2mvUeB

Jul 6, 2023 · 39 followers View post →

Hammed Onilude (PhD)

@HammedOnilude · X

Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy https://t.co/6W7B5tpcLd

Jul 4, 2023 · 296 followers View post →